Validating Integrative Multi-omics Approaches in Metabolic Syndrome-related Diseases
Condition(s) studied
Investigational drug(s) / intervention(s)
No intervention: no intervention
Study summary
This study aims to validate integrative multi-omics approaches for understanding complications related to metabolic syndrome. By combining genetic, transcriptomic, metabolomic, and microbiome data from participants with and without metabolic syndrome, the research seeks to determine which biological factors predict disease progression and how these insights can inform precision prevention and treatment strategies for metabolic disorders.
Eligibility
Primary outcome measure(s)
- Identification and validation of multi-omics biomarkers associated with metabolic syndrome and its complications — 5 years
Comprehensive integration of genomic, transcriptomic, metabolomic, and microbiome datasets to identify molecular signatures predictive of metabolic syndrome progression and related complications (e.g., cardiovascular disease, chronic kidney disease, fatty liver).
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Chang Gung Memorial Hospitals, Linkou | Taoyuan | Taiwan | Recruiting |
More Chang Gung Memorial Hospital trials in Taiwan
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07248371 on ClinicalTrials.gov ↗ ← All trials in Taiwan